Study to Evaluate the Pharmacokinetics of Selonsertib in Participants With Normal and Impaired Hepatic Function

Completed · Phase 1

Conditions studied: Diabetic Kidney Disease

In brief

The primary objective of this study is to evaluate the pharmacokinetics (PK) of selonsertib in participants with impaired hepatic function relative to matched, healthy controls.

Key facts

Study ID

NCT02509624

Run by

Gilead Sciences

People needed

52

Starts

2015-08-18

Expected to finish

2015-12-15

Last updated by the study team

2021-01-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

Where it is running

• Study site — Denver, Colorado, United States
• Study site — Miami, Florida, United States
• Study site — Orlando, Florida, United States
• Study site — Minneapolis, Minnesota, United States
• Study site — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.